Bile salt-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent

Hepatology

Volumn 50, Issue 1, 2009, Pages 143-154

  Chamulitrat, Walee ^a   Burhenne, Jürgen ^a   Rehlen, Tobias ^a   Pathil, Anita ^a   Stremmel, Wolfgang ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; LIVER PROTECTIVE AGENT; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; URSODEOXYCHOLYL 6 [(7 NITRO 2,1,3 BENZOXADIAZOL 4 YL)AMINO]HEXANOYLPHOSPHATIDYLETHANOLAMINE; URSODEOXYCHOLYLLYSOPHOSPHATIDYLETHANOLAMIDE; BILE ACID; LYSOPHOSPHATIDYLETHANOLAMINE; LYSOPHOSPHOLIPID; PHOSPHOLIPID; URSODEOXYCHOLIC ACID;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROTECTION; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG METABOLISM; DRUG UPTAKE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LIVER PROTECTION; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; CELL CULTURE; FATTY LIVER; HEPATITIS; METABOLISM;

ANIMALS; BILE ACIDS AND SALTS; CELLS, CULTURED; FATTY LIVER; HEPATITIS; LYSOPHOSPHOLIPIDS; MICE; PHOSPHOLIPIDS; URSODEOXYCHOLIC ACID;

EID: 67651148521     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22955     Document Type: Article

References (37)

1. Diehl AM. Non-alcoholic fatty liver disease. Semin Liver Dis 1999;19: 221-1219
2. Li Z, Agellon LB, Allen TM, Umeda M, Jewell L, Mason A, et al. The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab 2006;3:321-331.
3. Kharbanda K, Mailliard ME, Baldwin CR, Beckenhauer HC, Sorrell MF, Tuma DJ. Betaine attenuates alcoholic steatosis by restoring phosphatidylcholine generation via the phosphatidylethanolamine methyltransferase pathway. J Hepatol 2007;46:314-321. (Pubitemid 44959154)
4. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, et al. A lipidomic analysis of nonalcoholic fatty liver disease.HEPATOLOGY 2007; 46:1081-1090.
5. Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A, et al. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 2006;55:415-424. (Pubitemid 43268283)
6. Vance DE, Zhaoyu L, Jacobs R. Hepatic phosphatidylethanolamine N-methyltransferase, unexpected roles in animal biochemistry and physiology. J Biol Chem 2008;282:33237-33241. (Pubitemid 350159494)
7. Lieber CS. Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis. Alcohol 2004;34:9-19.
8. Lieber CS, Weiss DG, Groszmann R, Paronetto F, Schenker S; For the Veterans Affairs Cooperative Study 391 Group. II. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease. Alcohol Clin Exp Res 2003;27:1765-1772.
9. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001;96:2711-2717. (Pubitemid 32889210)
10. Stremmel W, Merle U, Zahn A, Autschbach F, Hinz U, Ehehalt R. Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut 2005;54:966-971. (Pubitemid 40873911)
11. Treede I, Braun A, Sparla R, Kühnel M, Giese T, Turner JR, et al. Antiinflammatory effects of phosphatidylcholine. J Biol Chem 2007;282: 27155-27164.
12. Fiorucci S, Antonelli E, Morelli O, Mencarelli A, Casini A, Mello T, et al. NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. Proc Natl Acad Sci U S A 2001;98:8897-8902. (Pubitemid 32678124)
13. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. HEPATOLOGY 2004;39: 770-778. (Pubitemid 38337657)
14. Guldutuna S, Zimmer G, Imhof M, Bhatti S, You T, Leuschner U. Molecular aspects of membrane stabilization by ursodeoxycholate. Gastroenterology 1993;104:1736-1744. (Pubitemid 23235466)
15. Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998;101:2790-2799. (Pubitemid 28294588)
16. Lekim D, Betzing H. Uptake and metabolism of polyene phosphatidylcholine in rat brain. Arzneimittelforschungs 1984;34:557-559. (Pubitemid 14145544)
17. Bechara FG, Georgas D, Sand M, Tomi N, Altmeyer P, Hoffmann K. Encapsulated fat necrosis after lipolysis of the calf with phosphatidylcholine. Dermatology 2008;216:180-181. (Pubitemid 351158587)
18. Innis SM, Davidson AG, Chen A, Dyer R, Melnyk S, James SJ. Increased plasma homocysteine and S-adenosylhomocysteine and decreased methionine is associated with altered phosphatidylcholine and phosphatidylethanolamine in cystic fibrosis. J Pediatr 2003;143:351-356. (Pubitemid 37188320)
19. Bai J, Cederbaum AI. Overexpression of catalase in the mitochondrial or cytosolic compartment increases sensitivity of HepG2 cells to tumor necrosis factor-alpha-induced apoptosis. J Biol Chem 2000;275:19241-19249.
20. Kullak-Ublick GA, Beuers U, Paumgartner G. Molecular and functional characterization of bile acid transport in human hepatoblastoma HepG2 cells. HEPATOLOGY 1996;23:1053-1060. (Pubitemid 26137046)
21. Esko JD, Matsuoka KY. Biosynthesis of phosphatidylcholine from serum phospholipids in Chinese hamster ovary cells deprived of choline. J Biol Chem 1983;258:3051-3057.
22. Sautin YY, Crawford JM, Svetlov SI. Enhancement of survival by LPA via Erk1/Erk2 and PI3-kinase/Akt pathways in a murine hepatocyte cell line. Am J Physiol Cell Physiol 2001;281:C2010-C2019. (Pubitemid 33775047)
23. Qiao L, Yacoub A, Studer E, Gupta S, Pei XY, Grant S, et al. Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes. HEPATOLOGY 2002;35:779-789. (Pubitemid 34258371)
24. Raufman J-P, Shant J, Guo CY, Roy S, Cheng K. Deoxycholyltaurine rescues human colon cancer cells from apoptosis by activating EGFR-dependent PI3K/Akt signaling. J Cell Physiol 2008;215:538-549.
25. Cui Z, Houweling M. Phosphatidylcholine and cell death. Biochim Biophys Acta 2002;1585:87-96.
26. Mallampalli RK, Ryan AJ, Salome RG, Jackowski S. Tumor necrosis factor- alpha inhibits expression of CTP:phosphocholine cytidylyltransferase. J Biol Chem 2000;275:9699-9708. (Pubitemid 30185203)
27. Ikegami T, Matsuzaki Y, Al Rashid M, Ceryak S, Zhang Y, Bouscarel B. Enhancement of DNA topoisomerase I inhibitor-induced apoptosis by ursodeoxycholic acid. Mol Cancer Ther 2006;5:68-79.
28. Scaffidi C, Schmitz I, Krammer PH, Peter ME. The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem 1999;274:1541-1548. (Pubitemid 129507745)
29. Jackowski S, Fagone P. CTP: phosphocholine cytidylyltransferase: paving the way from gene to membrane. J Biol Chem 2005;280:853-856.
30. Sasaki H, Kume H, Nemoto A, Narisawa S, Takahashi N. Ethanolamine modulates the rate of rat hepatocyte proliferation in vitro and in vivo. Proc Natl Acad Sci U S A 1997;94:7320-7325. (Pubitemid 27345313)
31. Houweling M, Tijburg LB, Vaartjes WJ, van Golde LM. Phosphatidylethanolamine metabolism in rat liver after partial hepatectomy. Control of biosynthesis of phosphatidylethanolamine by the availability of ethanolamine. Biochem J 1992;283:55-61.
32. Waite KA, Vance DE. Dimethylethanolamine does not prevent liver failure in phosphatidylethanolamine N-methyltransferase-deficient mice fed a choline-deficient diet. Biochim Biophys Acta 2004;1636:175-182.
33. Güldütuna S, Deisinger B, Weiss A, Freisleben HJ, Zimmer G, Sipos P, et al. Ursodeoxycholate stabilizes phospholipid-rich membranes and mimics the effect of cholesterol: investigations on large unilamellar vesicles. Biochim Biophys Acta 1997;1326:265-274. (Pubitemid 27272131)
34. Heuman DM, Bajaj R. Ursodeoxycholate conjugates protect against disruption of cholesterol-rich membranes by bile salts. Gastroenterology 1994;106:1333-1341. (Pubitemid 24129252)
35. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase- 3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998;12:3499-3511. (Pubitemid 28553242)
36. Cheng K, Xie G, Raufman JP. Matrix metalloproteinase-7-catalyzed release of HB-EGF mediates deoxycholyltaurine-induced proliferation of a human colon cancer cell line. Biochem Pharmacol 2007;73:1001-1012. (Pubitemid 46283578)
37. Oh HY, Namkoong S, Lee SJ, Por E, Kim CK, Billiar TR, et al. Dexamethasone protects primary cultured hepatocytes from death receptor-mediated apoptosis by upregulation of cFLIP. Cell Death Differ 2006;13:512-523.